Pharma Focus Asia

Cambrex Corporation invests around $50 million for expansion of lowa API plant

Introduction:

Cambrex Corporation announced plans that it has initiated the second significant expansion of its Charles City, Iowa facility with an investment of approx $50 million.

Features:

This investment includes a state of the art cGMP production facility and related supporting infrastructure. This project is expected to be completed in early 2016.

The new manufacturing facility will initially add a total of 70 cubic meters of glass lined and hastelloy reactors ranging in size from 7m3 to 16m3 along with 6m2 hastelloy filter dryers to provide a flexible, multi-purpose configuration. The facility will be designed to the highest regulatory and safety standards, capable of handling potent APIs at an OEL down to 1µg/m3 and will significantly increase the Company’s cGMP manufacturing capabilities.

The facility is also expandable with the ability to add additional capacity on a short timeline. The capacity is being added along with 45,000 square feet of new fully cGMP, temperature and humidity controlled warehouse space.

Specifications:

Company NameCambrex Corporation
LocationIowa
TypeExpansion
End Year2016
Estimated CostApprox $50 million
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference